Strategic Partnerships Fairtility has established multiple international partnerships (First Fertility, TWIG Fertility, Next Fertility) to deploy CHLOE AI across clinics and labs, signaling a channel-focused expansion strategy and increasing opportunities to upsell integration, training, and support services.

AI in IVF Growth The core offering CHLOE and related AI decision-support tools across oocyte and embryo assessment suggests strong demand among embryology and clinical teams for efficiency gains and standardization, presenting opportunities for expansion into additional clinics and lab networks.

Global Reach Client adoption spans Spain and Canada with ongoing lab deployments, indicating a scalable international model and potential for further cross-border sales to fertility networks and specialty clinics seeking transparent AI decision support.

Recognition Momentum Industry awards and media coverage, such as MedTech Breakthrough recognition for CHLOE and press announcements of partnerships, enhance credibility for enterprise sales cycles and can shorten procurement timelines with prospective hospital and clinic buyers.

Financial Position With a revenue band of one to ten million and a healthy funding cushion of nineteen million, Fairtility has resources to support sales acceleration, onboarding, and customer success programs necessary for rapid deployment in multi-site networks.